Glenmark signs a deal to market Cosmo Pharma's acne cream in Europe and South Africa

Glenmark Pharmaceuticals stated on Wednesday that its subsidiary has signed distribution and licensing agreements for Winlevi, which is used to treat acne, with Cosmo Pharmaceuticals NV.

Glenmark Specialty SA, a Glenmark Pharma subsidiary, will market and distribute Winlevi throughout Europe and South Africa, according to a stock exchange filing.

According to the agreements, Glenmark Speciality SA will get exclusive rights to commercialize Winlevi in 15 EU countries and South Africa from Cassiopeia, a subsidiary of Cosmo.

Glenmark received rights in 15 EU countries: Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, and Sweden.

Cassiopeia will be responsible for Centralized Marketing Authorization (CMA) at the European Medicines Agency (EMA), while Glenmark will be responsible for product registration in South Africa and the United Kingdom.

Glenmark Pharmaceuticals, a listed company, said that Cosmo will be the only supplier of the medicine.

Cassiopea will receive a $5 million upfront payment, as well as double-digit regulatory and sales milestones and agreed-upon double-digit royalties on net sales.

The United States Food and Drug Administration (USFDA) has cleared Winlevi for the treatment of acne in patients aged 12 and up.

The market for acne in the EU is predicted to expand from $928.7 million in 2021 to $1,297 million in 2028. Acne affects more than 90% of persons aged 11 to 30 years in Europe, with a high prevalence among teens fueling the market's rise.